Trichuris suis Oozyten (TSO®) in remittent-recurrent Multiple Sclerosi
Trichuris suis Oozyten (TSO®) in remittent-recurrent Multiple Sclerosis (MS) and Clinically Isolated Syndrom (CIS)
What it found
The trial ended early for another reason (see below).
What was tested
Treatment tested
- Trichuris suis ova (eggs), embryonated, viable
What it measured
Main measures
Number of new t2 lesions in cMRI
MRI lesions
Other measures (1)
Volume of new T2 lesions
MRI lesions
Who could take part
Early (CIS/RIS)
Show the full criteria
Inclusion criteria
Inclusion: - Male and female patients between 18 and 65 years Exclusion: - Patients which receive or have received in the last 3 months a therapy with IFN-β, Mitoxantron, Copaxone, Natalizumab or another immunsupressive or immunmodulatory treatment
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
To test the efficacy of TSO® in MS and CIS patients, measured as number of new T2 lesions in cMRI after a 12 months treatment - compared to placebo.
Loading reviews and guidelines…
History
Started
Feb 2011